NYSE: CATX - Perspective Therapeutics, Inc.

Yield per half year: -69.59%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Perspective Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc.

more details
and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2005-11-10
ISIN US46489V1044
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.perspectivetherapeutics.com
Цена ао 1.24
Change price per day: -3.04% (3.29)
Change price per week: +11.93% (2.85)
Change price per month: -22.57% (4.12)
Change price per 3 month: -74.62% (12.57)
Change price per half year: -69.59% (10.49)
Change price per year: +697.5% (0.4)
Change price per 3 year: +659.52% (0.42)
Change price per 5 year: +608.89% (0.45)
Change price per 10 year: 0% (3.19)
Change price per year to date: -70.1% (10.67)
All parameters

Underestimation

Title Value Grade
P/S 133.02 1
P/BV 17.29 1
P/E 0 0
EV/EBITDA -62.27 0
Total: 0.875

Efficiency

Title Value Grade
ROA, % -25.25 0
ROE, % -26.85 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1163 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -2.68 0
Yield Ebitda, % 179.96 10
Yield EPS, % 42.79 6
Total: 7.2
More

Institutions Volume Share, %
Vanguard Group Inc 13213750 2.25
Baker Brothers Advisors, LLC 7639703 1.3
Blackrock Inc. 4538389 0.77
Geode Capital Management, LLC 2516649 0.43
Ghost Tree Capital, LLC 1600000 0.27
Osterweis Capital Management, Inc. 1582100 0.27
HighTower Advisors, LLC 1332238 0.23
Perkins Capital Management, Inc. 700000 0.12
State Street Corporation 671524 0.11
Taylor & Morgan Wealth Management, LLC 625000 0.11

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Russell 2000 Growth ETF 0.04295 38.04 0.6026
iShares Morningstar Small-Cap Growth ETF 0.02697 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.02697 587.89 0.72598
iShares Morningstar Small-Cap ETF 0.01351 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.01351 391.25 1.60498
iShares Russell 3000 ETF 0.00132 24.83 1.43482



Head Job title Payment Year of birth
Mr. Johan M. Spoor CEO & Director 855.78k 1972 (53 years)
Mr. Jonathan R. Hunt CFO and Principal Financial & Accounting Officer 944.35k 1967 (58 years)
Mr. Shane Cobb Executive Vice President of Operations N/A
Dr. Michael K. Schultz Ph.D. Chief Science Officer N/A
Mr. Andrew Bright Executive Vice President of Brachytherapy N/A
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 633.14k 1966 (59 years)
Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer N/A
Dr. Frances L. Johnson M.D. Chief Innovation Officer N/A
Mr. David Hauser Ph.D. Senior Vice President of Clinical Operations N/A
Steve Keefe Senior Vice President of Clinical Development

Address: United States, Richland. WA, 350 Hills Street - open in Google maps, open in Yandex maps
Website: https://www.perspectivetherapeutics.com